Diurnal variation of soluble CD40 ligand in patients with acute coronary syndrome. Soluble CD40 ligand and diurnal variation

Thrombosis Research

Volumn 123, Issue 4, 2009, Pages 617-621

  Dominguez Rodriguez, Alberto ^a   Abreu Gonzalez, Pedro ^b   Garcia Gonzalez, Martín J ^a   Kaski, Juan Carlos ^c  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Acute coronary syndrome; Diurnal variation; Preanalytical conditions; Soluble CD40 ligand; ST segment elevation myocardial infarction

Indexed keywords

CD40 LIGAND;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLOOD SAMPLING; CIRCADIAN RHYTHM; CONTROLLED STUDY; DARKNESS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION; HUMAN; ILLUMINATION; LIGHT; LIGHT DARK CYCLE; MAJOR CLINICAL STUDY; MALE; NURSE; PRIORITY JOURNAL; SLEEP; ST SEGMENT ELEVATION;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CD40 LIGAND; CIRCADIAN RHYTHM; HUMANS; MALE; MIDDLE AGED;

EID: 58649110005     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.05.006     Document Type: Article

References (27)

1. Henn V., Slupsky J.R., Grafe M., Anagnostopoulos I., Forster R., Muller-Berghaus G., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391 (1998) 591-594
2. Henn V., Steinbach S., Buchner K., Presek P., and Kroczek R.A. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 98 (2001) 1047-1054
3. Apple F.S., Wu A.H., Mair J., Ravkilde J., Panteghini M., Tate J., et al. Committee on standardization of markers of cardiac damage of the IFCC. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 51 (2005) 810-824
4. Young M.E. The circadian clock within the heart: potential influence on myocardial gene expression, metabolism, and function. Am J Physiol Heart Circ Physiol 290 (2006) H1-H16
5. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia M., Ferrer J., de la Rosa A., Vargas M., et al. Light/dark patterns of interleukin-6 in relation to the pineal hormone melatonin in patients with acute myocardial infarction. Cytokine 26 (2004) 89-93
6. Dominguez-Rodriguez A., Garcia-Gonzalez M., Abreu-Gonzalez P., Ferrer J., and Kaski J.C. Relation of nocturnal melatonin levels to C-reactive protein concentration in patients with ST-segment elevation myocardial infarction. Am J Cardiol 97 (2006) 10-12
7. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia-Gonzalez M.J., and Reiter R.J. Relation of nocturnal melatonin levels to serum matrix metalloproteinase-9 concentrations in patients with myocardial infarction. Thromb Res 120 (2007) 361-366
8. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia-Gonzalez M.J., Samimi-Fard S., Kaski J.C., and Reiter R.J. Light/dark patterns of soluble vascular cell adhesion molecule-1 in relation to melatonin in patients with ST-segment elevation myocardial infarction. J Pineal Res 44 (2008) 65-69
9. Jaffe A.S., Babuin L., and Apple F.S. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol 48 (2006) 1-11
10. Conde I.D., and Kleiman N.S. Soluble CD40 ligand in acute coronary syndromes [Letter]. N Engl J Med 348 (2003) 2575-2577
11. Bereczki D., Nagy E., Pal A., Magyar M.T., and Balla J. Should soluble CD40 ligand be measured from serum or plasma samples [Letter]?. Arterioscler Thromb Vasc Biol 23 (2003) 1129-1130
12. Ahn E.R., Lander G., Jy W., Bidot C.J., Jimenez J.J., Horstman L.L., et al. Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. Thromb Res 114 (2004) 143-148
13. Halldorsdottir A.M., Stroker J., Porche-Sorbet R., and Eby C.S. Soluble CD40 ligand measurement inaccuracies attributable to specimen type, processing time, and ELISA method. Clin Chem 51 (2005) 1054-1057
14. Weber M., Rabenau B., Stanisch M., Elsaesser A., Mitrovic V., Heeschen C., et al. Influence of sample type and storage conditions on soluble CD40 ligand assessment. Clin Chem 52 (2006) 888-891
15. Van de Werf F., Ardissino D., Betriu A., Cokkinos D.V., Falk E., Fox K.A., et al. Management of acute myocardial infarction in patients with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 24 (2003) 28-66
16. Yan J.C., Zhu J., Gao L., Wu Z.G., Kong X.T., Zong R.O., et al. The effect of elevated serum soluble CD40 ligand on the prognostic value in patients with acute coronary syndromes. Clin Chim Acta 343 (2004) 155-159
17. Meier-Ewert H.K., Ridker P.M., Rifai N., Price N., Dinges D.F., and Mullington J.M. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 47 (2001) 426-430
18. Tayebjee M.H., Lip G.Y., Blann A.D., and MacFadyen R.J. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb Res 115 (2005) 205-210
19. Manolio T. Novel risk markers and clinical practice. N Engl J Med 349 (2003) 1587-1589
20. Vasan R. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113 (2006) 2335-2362
21. Schonbeck U., Varo N., Libby P., Buring J., and Ridker P.M. Soluble CD40L and cardiovascular risk in women. Circulation 104 (2001) 2266-2268
22. Heeschen C., et al., for the CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348 (2003) 1104-1111
23. Varo N., Libby P., Morrow D.A., Nuzzo R., Cannon C.P., Braunwald E., et al. Soluble CD40L: risk prediction after acute coronary síndromes. Circulation 108 (2003) 1049-1052
24. Kinlay S., et al., for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 110 (2004) 386-391
25. Ivandic B.T., Spanuth E., Haase D., Lestin H.G., and Katus H.A. Increased plasma concentrations of soluble CD40 ligand in acute coronary syndrome depend on in vitro platelet activation. Clin Chem 53 (2007) 1231-1234
26. Sardella G., Mariani P., D'Alessandro M., De Luca L., Pierro M., Mancone M., et al. Early elevation of interleukin-1 beta and interleukin-6 levels after bare or drug-eluting stent implantation in patients with stable angina. Thromb Res 117 (2006) 659-664
27. Rudnicka A.R., Rumley A., Lowe G.D., and Strachan D.P. Diurnal, seasonal, and blood-processing patterns in levels of circulating fibrinogen, fibrin D-dimer, C-reactive protein, tissue plasminogen activator, and von Willebrand factor in a 45-year-old population. Circulation 115 (2007) 996-1003